Clinical trial
Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or…
NCT00034164 · Achieve Life Sciences, Industry · Completed
Key facts
| NCT number | NCT00034164 |
|---|---|
| Title | Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer |
| Official title | A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer |
| Lead sponsor | Achieve Life Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | S-8184 Paclitaxel Injectable Emulsion |
| Enrollment | 52 |
| Start date | Apr 1, 2002 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 24, 2002 |
| Last update posted | Jun 4, 2009 |
| Countries | Russia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: